Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782639 · ClinicalTrials.gov registry record · Phase 4
Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients
A Phase 4 study, sponsored by Bracco Diagnostics.
- Terminated
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT00782639: Clinical Trial Phase 4 study, sponsored by Bracco Diagnostics.
NCT00782639 is a Phase 4 study that was terminated before completion, run by Bracco Diagnostics. The registered enrollment target is 23 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00782639, a Phase 4 study, was terminated before completion, sponsored by Bracco Diagnostics.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN) following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque 320) in patients with moderate-to-severe chronic kidney disease and diabetes mellitus undergoing cardiac angiography.
Primary Outcome
The number of participants who presented with CIN (defined as an increase in Serum Creatinine (SCr) from baseline greater than or equal to 0.5 mg/dL following the administration of iopamidol-370 or iodixanol 320 while undergoing cardiac angiography). Since CIN is a prospectively-defined outcome measure of the trial, patients experiencing CIN were not reported as having an adverse event.
Interventions
- DRUG iodixanol
- DRUG Iopamidol injection 76%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
Why NCT00782639 stopped before completion
NCT00782639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which iodixanol is the first listed.
NCT00782639 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00782639 about?
NCT00782639 is a clinical study titled "Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients". The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN) following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque 320) in patients with moderate-to-severe chronic kidney disease and diabetes mellitus undergoing cardiac angiography.
What is the current status of trial NCT00782639?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2009-03. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00782639?
The interventions under investigation include: iodixanol (DRUG), Iopamidol injection 76% (DRUG).
Who is sponsoring clinical trial NCT00782639?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00782639's enrollment target sits among peer trials
23 1725th of 2000 higher than 270 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia